Fibrillary Glomerulonephritis Clinical Trial
Official title:
A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis
This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.
This is a Phase II, open-label pilot study to determine if the use of Rituximab reduces proteinuria over a 12 month period and is there preservation of kidney function with the use of this study drug. Each patient will be treated with 2 intravenous infusions of rituximab 1000 mg, two weeks apart for a total of 2 doses. Each patient will be retreated with identical 2 intravenous infusions of rituximab, two weeks apart at 6 months after the first infusion, irrespective of cluster of differentiation (CD) 20+ cell counts. Thus, each participant will receive 4 infusions of rituximab. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT06295770 -
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
|
Phase 2 | |
| Active, not recruiting |
NCT05546047 -
A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients
|
Phase 4 |